In leukemia and lymphoma, PRMT5 silences RB family members (RB1, RBL1, and RBL2) via hypermethylation of H3R8 and H4R3, thereby disabling RB-mediated cell cycle control and promoting proliferation [317]. Here, PRMT5 is linked to leukemia.